

31 July 2012

## ASX ANNOUNCEMENT

### APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended June 2012.

The Company held cash reserves at the end of the period of \$1,209,000.

Research and development expenditure (\$204k), staff costs (\$127k), and general overheads (\$79k) accounted for the bulk of the operating cash flows for the quarter.

The Company continues to have a line of credit of \$400,000 to ensure adequate funding of the Company.

Medical Australia have released Tuta-branded burettes fitted with MediFlush, Analytica's unique flushing feature. The MediFlush feature reduces costs and also address infection control issues associated with medicine delivery in conventional burettes. These issues have previously required hospitals to use a higher cost, alternative solutions.

Marketing initiatives are under way in Europe and the United States of America, and Analytica has recently performed successful pilot production of units at a new factory in China for the USA market.

The development of the pelvic floor exercise system proceeds on schedule with clinical evaluation of current prototypes underway.

For, and on behalf of the board,

**Dr Michael Monsour**

Chairman, Board of Directors

*Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of Class I and IIa medical devices. Analytica's focus is on the product development and commercialisation of a range of medical devices and pharmaceutical implants.*



# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30 June 2012

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for		
(a) staff costs	(127)	(433)
(b) advertising and marketing	-	(16)
(c) research and development	(204)	(611)
(d) leased assets	-	-
(e) other working capital	(79)	(482)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	23	27
1.5 Interest and other costs of finance paid	-	(19)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	5
(b) R & D Tax Concession	-	261
(c) Royalty Income	-	-
<b>Net operating cash flows</b>	<b>(387)</b>	<b>(1268)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

		Current quarter \$A'000	Year to date (12 months) \$A'000
1.8	Net operating cash flows (carried forward)	<b>(387)</b>	<b>(1268)</b>
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	(20)	(20)
	(d) physical non-current assets	(1)	(4)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	8
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes )	-	-
	<b>Net investing cash flows</b>	<b>(21)</b>	<b>(16)</b>
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>(408)</b>	<b>(1284)</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares	-	2760
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	(269)
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	-	-
	<b>Net financing cash flows</b>	<b>-</b>	<b>2491</b>
	<b>Net increase (decrease) in cash held</b>	<b>(408)</b>	<b>1207</b>
1.21	Cash at beginning of quarter/year to date	1617	2
1.22	Exchange rate adjustments to item 1.20	-	-
<b>1.23</b>	<b>Cash at end of quarter</b>	<b>1209</b>	<b>1209</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	13
1.26	Explanation necessary for an understanding of the transactions	
	Payment of director's fees and compulsory superannuation.	

**Non-cash financing and investing activities**

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A
-----

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A
-----

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	-
3.2	Credit standby arrangements	-	-

---

+ See chapter 19 for defined terms.

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1209	1617
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	1209	1617

**Acquisitions and disposals of business entities**

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date: 31 July 2012

Print name: Tom Rowe, Company Secretary

---

+ See chapter 19 for defined terms.